combined

ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study showsESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows

ESOC 2025: Combined oral contraceptives triple risk of cryptogenic stroke in young women, new study shows

HELSINKI, May 20, 2025 /PRNewswire/ -- New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that…

3 hours ago
Exosens: Availability of documents and information relating to the Combined General Meeting of 23 May 2025Exosens: Availability of documents and information relating to the Combined General Meeting of 23 May 2025

Exosens: Availability of documents and information relating to the Combined General Meeting of 23 May 2025

PRESS RELEASEMÉRIGNAC, FRANCE – 30 APRIL 2025 EXOSENS ANNOUNCES THE AVAILABILITY OF DOCUMENTS AND INFORMATION RELATING TO THE COMBINED GENERAL MEETING…

3 weeks ago

More races, more excitement for Nordic Combined fans at Trondheim 2025 WSC

Mar 18, 2025 - Among the success stories of the Trondheim 2025 Nordic World Ski Championships (WSC) was the addition…

2 months ago
Combined General Meeting of January 31, 2025Combined General Meeting of January 31, 2025

Combined General Meeting of January 31, 2025

Paris, France – January 31, 2025 – The Combined Annual General Meeting of Atos SE shareholders convened to approve the 2023…

4 months ago
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity…

6 months ago